NorthWest Biotherapeutics Inc (NWBO)

[791branko]

Thanks, Branko, for this work. Would you mind expanding on this?

Quote:Cross-over effect on Control arm is a wild card but I am not expecting it to be substantial

Astavankra,

The survival affect on Control arm patients crossing-over onto DCVax-L is very difficult to estimate.
A couple of years ago researchers were thinking DCVax-L would not be effective on bulky tumors so it would not be ineffective after tumor recurrence.
But now that stance looks to have changed, we are about to begin a rGBM trial with L alone versus L + CI Yervoy. So I believe researches are now considering L may well have efficacy after tumor recurrence.